查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
糖尿病腎病變的全球市場:預測(2022年～2028年)
市場調查報告書
商品編碼
1123154

糖尿病腎病變的全球市場:預測(2022年～2028年)

Global Diabetic Nephropathy Market Research and Forecast 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

全球糖尿病腎病變的市場規模在預測期間內預計將以5.3％的年複合成長率擴大。促成市場增長的主要因素是由於世界各地人們久坐不動的生活方式和不良的飲食習慣，糖尿病患病率不斷上升。政府舉措，例如增加開發糖尿病治療先進技術的支出和增加對家庭診斷技術的需求，正在推動市場的增長。

按本報告提供全球糖尿病腎病變市場相關調查，市場概要，以及各適應症，診斷，不同治療，各地區的趨勢，及的加入此市場的主要企業的簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析
  • COVID-19對主要加入企業帶來的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 機會

第5章 市場區隔

  • 全球糖尿病腎病變市場，各適應症
    • 第一型糖尿病
    • 第二型糖尿病
  • 全球糖尿病腎病變市場，診斷
    • 尿液檢查
    • 影像檢查
    • 血液檢驗
    • 腎功能檢驗
    • 腎切片檢查
  • 全球糖尿病腎病變市場，不同治療
    • 藥物治療
    • 腎臟透析
    • 腎臟移植

第6章 地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • Abbvie, Inc.
  • Aerpio Pharmaceuticals, Inc.
  • Antisense Therapeutics, Ltd.
  • Astellas Pharma Europe, Ltd.
  • AstraZeneca plc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cellmid, Ltd.
  • ChemoCentryx, Inc.
Product Code: OMR2018287

Global Diabetic Nephropathy Market Size, Share & Trends Analysis Report by Indication (Diabetes Type-1, and Diabetes Type-2), By Diagnosis (Urine Test, Imaging Test, Blood Test, Renal Function Test, and Renal Biopsy), and By Treatment (Medications, Kidney Dialysis, Kidney Transplant) Forecast Period 2021-2027

The global diabetic nephropathy market is anticipated to grow at a significant CAGR of 5.3% during the forecast period. Major factors contributing to the growth of the global diabetic nephropathy market include the increasing prevalence of diabetic patients across the globe due to sedentary lifestyles and faulty dietary habits of the population across the globe. Initiatives taken by the government by rising spending on the development of advanced technologies for the treatment of the disease and increasing demand for home-based diagnostic technologies are fueling the market growth.

Stringent regulatory policies for the approval of diabetic nephropathy drugs and the increasing number of patent expirations are some of the factors hindering the growth of the market. Some of the other factors responsible for restraining market growth are the high cost of imaging devices and the long duration of clinical trials. However, advancements in diagnostic imaging technology are expected to propel market growth in the near future.

Diabetic Nephropathy is a clinical syndrome related to damage or impairment of the kidney and majorly affects type-1 and type-2 diabetic patients. It can cause severe complications in the kidney such as macroalbuminuria, in which more than 300mg of urinary albumin is excreted by the kidney in the period of 24-hours. The diabetic nephropathy market is one of the major causes of the occurrence of chronic kidney diseases and renal failure across the globe.

Impact of COVID-19 Pandemic on Global Diabetic Nephropathy Market

During the initial COVID-19 pandemic the diagnosis segment had experienced a slight reduction, however, it soon got back the momentum in its growth. According to the National Center of Biotechnology Information, there was an 89% probability that diabetic nephropathy patients get infected by COVID-19, 5% more probability for the need of hospitality, and 21% probability of fatality. As the risk of COVID-19 severity increases in diabetic patients, thus governments across the globe are taking extra precautionary measures for diabetic patients.

Segmental Outlook

The global diabetic nephropathy market is segmented based on indication, diagnosis, and treatment. Based on the indication, the market is segmented into diabetes type-1, and diabetes type-2. Based on the diagnosis, the market is segmented into urine test, imaging test, blood test, renal function test, and renal biopsy. Apart from this, by treatment, the market is segmented into medications, kidney dialysis, and kidney transplant.

Global Diabetic Nephropathy Market Share by Treatment, 2020 (%)

Global Diabetic Nephropathy Market Share by Treatment

The Medication holds the major share in the Global Diabetic Nephropathy Market

The medication is the primary treatment given to patients with diabetic nephropathy, thus it occupies the major market share. The angiotensin-converting enzyme inhibitors are the most common medication given to the patients as it is safest and efficient in treating diabetic nephropathy. Most of the medication drugs of diabetic nephropathy are under pre-clinical trials or II phases of development. Acupuncture is immerging in the market and needs to be researched more as it had no side effects, economical, and effective treatment of diabetic nephropathy. Kidney transplant and kidney dialysis have a small share of the diabetic nephropathy market as these are the end-stage treatment and are expensive too.

In terms of indication, diabetes type-2 occupies the major share as they are at the major risk of getting infected by diabetic nephropathy. The American Diabetes Association had suggested that patients with diabetes type-2 should start diagnosis of diabetic nephropathy immediately after the detection of diabetes. Whereas, patients with diabetes type-1 can diagnose themselves after five years of a diabetes diagnosis. Urine and blood test are the most common diagnostic method used as this is the initial level of test performed and is economical too, while renal functioning and biopsy are the end-stage and expensive tests. Imaging tests are emerging in the market with steady growth.

Regional Outlooks

The global diabetic nephropathy market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others, and the Rest of the World (the Middle East and Africa, and Latin America).

Global Diabetic Nephropathy Market Growth, by Region 2021-2027

Global Diabetic Nephropathy Market Growth, by Region

The North America is Dominant in the Global Diabetic Nephropathy Market.

North America holds a dominant position in the global diabetic nephropathy market, followed by Europe. This is mainly owing to rising awareness amongst the population about the various kidney-related diseases. High reimbursement policies by the government in the healthcare sector and demand for continuous monitoring of diabetes are some factors that are significantly contributing towards the market growth in the region. In Europe, the growing demand for home-based diagnosis of the disease, especially among the geriatric population is one of the major factors fueling the market growth. The Asia Pacific is projected to exhibit the fastest growth in the global diabetic nephropathy market over the forecast period. This is due to the large pool of diabetic population in the region, especially in Japan and Southeast Asian countries.

Market Players Outlook

The major companies serving the global diabetic nephropathy market include Abbott Laboratories, Bayer AG, AstraZeneca, Xortx Therapeutics Inc., GlaxoSmithKline plc, Astellas Pharma, Inc., and AbbVie Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In May 2021, the University of South Australia had found a new enzyme, NEDD4-2 which is effective in treating critical kidney diseases.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global diabetic nephropathy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Diabetic Nephropathy Market
  • Recovery Scenario of Global Diabetic Nephropathy Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Diabetic Nephropathy Market by Indication
    • 5.1.1. Diabetes Type-1
    • 5.1.2. Diabetes Type-2
  • 5.2. Global Diabetic Nephropathy Market by Diagnosis
    • 5.2.1. Urine Test
    • 5.2.2. Imaging Test
    • 5.2.3. Blood Test
    • 5.2.4. Renal Function Test
    • 5.2.5. Renal Biopsy
  • 5.3. Global Diabetic Nephropathy Market by Treatment
    • 5.3.1. Medications
    • 5.3.2. Kidney Dialysis
    • 5.3.3. Kidney Transplant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Abbvie, Inc.
  • 7.3. Aerpio Pharmaceuticals, Inc.
  • 7.4. Antisense Therapeutics, Ltd.
  • 7.5. Astellas Pharma Europe, Ltd.
  • 7.6. AstraZeneca plc.
  • 7.7. Bayer AG
  • 7.8. Bristol-Myers Squibb Co.
  • 7.9. Cellmid, Ltd.
  • 7.10. ChemoCentryx, Inc. **List not exhaustive

LIST OF TABLES

  • 1. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 2. GLOBAL DIABETES TYPE-1 NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL DIABETES TYPE-2 NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 5. GLOBAL DIABETIC NEPHROPATHY URINE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL DIABETIC NEPHROPATHY IMAGING TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL DIABETIC NEPHROPATHY BLOOD TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL DIABETIC NEPHROPATHY RENAL FUNCTIONING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL DIABETIC NEPHROPATHY RENAL BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 11. GLOBAL MEDICATIONS FOR DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL KIDNEY DIALYSISFOR DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL KIDNEY TRANSPLANTFOR DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 19. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 20. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 21. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 22. EUROPEAN DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 27. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 28. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL DIABETIC NEPHROPATHY MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL DIABETIC NEPHROPATHY MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL DIABETIC NEPHROPATHY MARKET, 2021-2027 (%)
  • 4. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY INDICATION, 2020 VS 2027 (%)
  • 5. GLOBAL DIABETES TYPE-1 NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL DIABETES TYPE-2 NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 8. GLOBAL DIABETIC NEPHROPATHY URINE TEST FOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL IMAGING TEST FOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL BLOOD TEST FOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL RENEAL FUNCTIONING TEST FOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL RENAL BIOPSY FOR DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 14. GLOBAL DIABETIC NEPHROPATHY MEDICATION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL DIABETIC NEPHROPATHY KIDNEY DIALYSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL DIABETIC NEPHROPATHY KIDNEY TRANSPLANT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL DIABETIC NEPHROPATHY ACUPUNCTURE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBAL DIABETIC NEPHROPATHY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 19. US DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 20. CANADA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 21. UK DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. ITALY DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. REST OF EUROPE DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. INDIA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. CHINA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD DIABETIC NEPHROPATHY MARKET SIZE, 2020-2027 ($ MILLION)